New Delhi, May 24
Ranbaxy Laboratories Ltd has said that the World Health Organisation (WHO) has included four of its additional anti-retroviral (ARV) products in its pre-qualification list.
The products approved by WHO are Efavirenz 600 mg tablets, Efavirenz 200 mg capsules, Stavudine 30 mg capsules and Stavudine 40 mg capsules, the company said in a statement.
"This is a significant development. We strongly feel that generic ARVs are essential in the struggle against HIV/AIDS and are committed to providing high quality, cost effective generics," the Ranbaxy CEO and Managing Director, Mr Malvinder Mohan Singh, said.
With these inclusions, Ranbaxy now has a total of 12 ARVs on the WHO pre-qualification list.
It also has three approvals from USFDA for ARVs, making it eligible for supplying to the US funded PEPFAR programme.
"Efavirenz is rapidly becoming a preferred drug in the HIV treatment programme in developing countries.
"The other newly listed drug, Stavudine, is also being widely used as a first line of therapy against AIDS. Both products increase customer choice enabling patients to access therapy easily, at affordable prices," Mr Singh said.
Ranbaxy has been providing ARVs at affordable prices to countries and patients afflicted by HIV/AIDS since 2001.